Relmada Therapeutics Inc (DE:4E2)

NASDAQ:4E2

4E2

Relmada Therapeutics

RESEARCH TOOLSreports

Relmada Therapeutics (4E2) Price & Analysis

0 Followers

4E2 Stock Chart & Stats

€5.75

-€0.01(-2.14%)

At close: Jan 08 4:00 PM EST

€5.75

-€0.01(-2.14%)

Day’s Range― - ―

52-Week Range€0.44 - €6.50

Previous CloseN/A

Volume0.00

Average Volume (3M)15.00

Market Cap

€580.06M

Enterprise Value€518.96M

Total Cash (Recent Filing)€233.96M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta0.76

Next Earnings

Aug 11, 2026

EPS Estimate

-0.16

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.11

Shares Outstanding104,890,220

10 Day Avg. Volume0

30 Day Avg. Volume15

Financial Highlights & Ratios

PEG Ratio0.07

Price to Book (P/B)2.20

Price to Sales (P/S)0.00

P/FCF Ratio-4.16

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€13.34

Price Target Upside132.07% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)-0.65

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessNDV-01 for high-grade non-muscle invasive bladder cancer showed an overall response rate of 85% and high-grade recurrence-free survival in patients with papillary disease of 83%.

Market PotentialRelmada announced in-licensing of Trigone's NDV-01 for treating NMIBC, which is seen as a multi-billion opportunity.

Safety And AdministrationNDV-01 was well-tolerated with no treatment-related adverse events greater than grade 1.

Bears Say

Development PrioritizationThe company is re-evaluating further development of ‘P11 (novel psilocybin) as part of its prioritization efforts.

Pipeline UncertaintyThe company ended the year with $27M in cash, and additional data and updates from the pipeline are awaited before making any substantive comments regarding the pipeline assets.

Valuation ConcernsAt this point, the product is not being added into the valuation, and the recommendation remains Market Perform.

Relmada Therapeutics News

Relmada Therapeutics files automatic mixed securities shelf

16:54 EDT Relmada Therapeutics (RLMD) files automatic mixed securities shelf Published first on TheFly – the ultimate source...

22d ago

RLMD

Relmada Therapeutics Increases Authorized Shares After Shareholder Vote

Relmada Therapeutics ( ($RLMD) ) has provided an update. Relmada Therapeutics, Inc. reported that on May 28, 2026,...

7d ago

RLMD

Relmada Therapeutics Charts Ambitious NDV-01 Phase 3 Path

Relmada Therapeutics Inc (($RLMD)) has held its Q1 earnings call. Read on for the main highlights of the...

22d ago

RLMD

Relmada Highlights NDV-01 Phase 2 Data, Phase 3 Plans

Relmada Therapeutics ( ($RLMD) ) has issued an update. On May 12, 2026, Relmada Therapeutics reported first-quarter 2026...

23d ago

RLMD

Relmada Therapeutics initiated with an Overweight at Piper Sandler

Piper Sandler initiated coverage of Relmada Therapeutics (RLMD) with an Overweight rating and $12 price target The firm...

2M ago

RLMD

Relmada Therapeutics Charts Aggressive Path After Earnings Call

Relmada Therapeutics Inc (($RLMD)) has held its Q4 earnings call. Read on for the main highlights of the...

3M ago

RLMD

Relmada Highlights NDV-01 Data, Funding in 2025 Results

The latest announcement is out from Relmada Therapeutics ( ($RLMD) ). Relmada Therapeutics reported audited fourth-quarter and full-year...

3M ago

RLMD

Relmada Therapeutics price target raised to $19 from $10 at Mizuho

Mizuho analyst Uy Ear raised the firm’s price target on Relmada Therapeutics (RLMD) to $19 from $10 and...

3M ago

RLMD

Relmada’s Withdrawn Phase 3 Bladder Cancer Trial: What It Means for RLMD Investors

Relmada Therapeutics Inc ($RLMD) announced an update on their ongoing clinical study. The Phase 3 study titled “A...

3M ago

RLMD

Relmada’s Withdrawn BOOST Trial Resets Expectations for NDV-01 and RLMD

Relmada Therapeutics Inc ($RLMD) announced an update on their ongoing clinical study. The BOOST study, officially titled “A...

3M ago

RLMD

Relmada Therapeutics Inc (RLMD) Q4 Earnings Cheat Sheet

Relmada Therapeutics Inc (RLMD) is scheduled to report 4th quarter earnings on 03/19/2026. Regarding Q4 estimates, Wall Street...

3M ago

RLMD

Morning News Wrap-Up 3/9/26: Monday’s Biggest Stock Market Stories!

Investors seeking the top stock market stories for Monday will want to check out the daily wrap-up. ...

3M ago

Midday Fly By: Hims & Hers reaches Novo deal, Live Nation settles with DOJ

The major averages were lower near noon, but well off earlier lows, amid the continued spike in oil...

3M ago

Why Is Relmada Therapeutics Stock (RLMD) Up Today?

Relmada Therapeutics stock took off after the company announced new study results and financing. ...

3M ago

RLMD

4E2 FAQ

What was Relmada Therapeutics Inc’s price range in the past 12 months?

Relmada Therapeutics Inc lowest stock price was €0.44 and its highest was €6.50 in the past 12 months.

What is Relmada Therapeutics Inc’s market cap?

Relmada Therapeutics Inc’s market cap is €580.06M.

When is Relmada Therapeutics Inc’s upcoming earnings report date?

Relmada Therapeutics Inc’s upcoming earnings report date is Aug 11, 2026 which is in 68 days.

How were Relmada Therapeutics Inc’s earnings last quarter?

Relmada Therapeutics Inc released its earnings results on May 12, 2026. The company reported -€0.188 earnings per share for the quarter, missing the consensus estimate of -€0.171 by -€0.017.

Is Relmada Therapeutics Inc overvalued?

According to Wall Street analysts Relmada Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Relmada Therapeutics Inc pay dividends?

Relmada Therapeutics Inc does not currently pay dividends.

What is Relmada Therapeutics Inc’s EPS estimate?

Relmada Therapeutics Inc’s EPS estimate is -0.16.

How many shares outstanding does Relmada Therapeutics Inc have?

Relmada Therapeutics Inc has 104,890,220 shares outstanding.

What happened to Relmada Therapeutics Inc’s price movement after its last earnings report?

Relmada Therapeutics Inc reported an EPS of -€0.188 in its last earnings report, missing expectations of -€0.171. Following the earnings report the stock price went up 7.5%.

Which hedge fund is a major shareholder of Relmada Therapeutics Inc?

Currently, no hedge funds are holding shares in DE:4E2

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Relmada Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-71.22%

Trailing 12-Months

Asset Growth

750.32%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Relmada Therapeutics Inc

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.

Relmada Therapeutics (4E2) Earnings & Revenues

Historic Earnings Reports

4E2 Earnings Call

Q1 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call conveyed predominantly positive momentum: robust phase 2 12-month efficacy and safety data for NDV-01, FDA alignment for a two-pathway Phase 3 registrational program, strengthened IP positioning via a provisional patent filing, and a materially improved balance sheet with ~$234M cash (runway into 2029). Operational advantages (office-based, short administration) and a planned Cipranolone proof-of-concept add to the upside. Key challenges include a significant rise in G&A expense, a modestly larger absolute net loss, patent prosecution uncertainty, and potential variability in Phase 3 patient populations which could affect measured efficacy. Overall, the highlights substantially outweigh the lowlights, but successful execution of the planned mid-2026 trial starts and subsequent enrollment/readouts remain critical.View all DE:4E2 earnings summaries

4E2 Stock 12 Month Forecast

Average Price Target

€13.34

▲(132.07% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"€8","17":"€17","-1":"-€1","3.5":"€3.5","12.5":"€12.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16.35704509,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€16.36</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.343905205,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€13.34</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.330765320000001,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€10.33</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,3.5,8,12.5,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6,6.796695776153846,7.5933915523076925,8.390087328461538,9.186783104615385,9.98347888076923,10.780174656923077,11.576870433076923,12.37356620923077,13.170261985384615,13.966957761538461,14.763653537692308,15.560349313846153,{"y":16.35704509,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6,6.564915785,7.12983157,7.6947473550000005,8.25966314,8.824578925,9.389494710000001,9.954410495000001,10.519326280000001,11.084242065000002,11.649157850000002,12.214073635000002,12.77898942,{"y":13.343905205,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6,6.333135793846154,6.666271587692308,6.999407381538462,7.3325431753846155,7.66567896923077,7.998814763076924,8.331950556923077,8.665086350769231,8.998222144615386,9.33135793846154,9.664493732307694,9.997629526153847,{"y":10.330765320000001,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.635,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.49,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.525,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.905,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.64,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.97,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.96,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.639,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.86,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.66,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.8,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.05,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >